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 Abstract                                                                                                            
Background: Chronic administration of morphine cause physical 
dependence but the exact mechanism of this phenomenon remains 
unclear. The aim of this study is the assessment of systemic 
and intracerebroventricular (icv) administration of ramelteon (a 
melatonin receptor agonist) on morphine physical dependence. 
Methods: 88 adult male rats were divided into 2 major groups, 
namely “systematic” and “central” administration of ramelteon. 
In the first category, systemic administration of ramelteon at 
various dosages (10, 20, and 40 mg/kg) was assessed on dependent 
animals and withdrawal signs were compared with positive 
(received morphine and saline as systemic administration), 
negative control (saline) and group under treatment by ramelteon 
(40 mg/kg) groups. In the second category, central administration 
of ramelteon at various dosages (25, 50, or 100 μg,) was assessed 
on dependent animals and withdrawal signs were compared with 
the positive control (received morphine and saline as icv) and 
negative control (saline) groups, and the group under treatment 
by ramelteon (50 μg/5 μl/rat). On the test day, all animals received 
naloxone (3 mg/kg) and were observed for withdrawal signs. Total 
withdrawal score (TWS) was also determined. Finally, to evaluate 
the stress level of dependent rats, blood cortisols were measured. 
Results: Central administration of ramelteon in all doses and 
systemic administration in high doses attenuate withdrawal 
syndrome in comparison with the dependent positive control 
group (P<0.05). Both central and systemic administrations of 
ramelteon can attenuate the blood cortisol level in comparison 
with the dependent positive control group (P<0.05). 
Conclusion: In conclusion, we found that central administration 
of ramelteon attenuated morphine withdrawal symptoms and 
cortisol level as a stress marker.
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 Introduction                                                                                            
Long-term administration of morphine has been accepted as 
the standard method for pain relief in patients with acute pain.1 
Long-term use of morphine, which is characterized by physical 
dependency, result in the onset of withdrawal syndrome when 
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mechanism which can vindicate dependence and 
withdrawal symptoms of morphine are not clear. 
Previous studies suggested that neurochemical 
dysfunction in nucleus accumbens followed by 
systemic morphine administration was the main 
reason for dependency to morphine. These studies 
suggested that, dopaminergic and serotonergic 
systems in nucleus accumbens have a critical role 
in dependence to morphine.3,4 
Melatonin, a hormone that control circadian 
rhythms (e.g. sleep and wake cycle), is made by 
a small gland in the brain known as the pineal 
gland.5 Recent studies demonstrate the critical 
role of melatonin in neuromodulation in nucleus 
accumbens. This hormone plays a significant 
role in the regulation of various neural processes 
such as pain perception.6-8 Previous studies 
have characterized the interaction between 
pineal melatonin and the serotonergic function. 
These studies have indicated that melatonin 
has potential effects on the modulation of 
serotonergic and dopaminergic cell bodies, which 
may relate to the mode of action of melatonin 
and its behavioral effects.9-11 Moreover, based 
on the results of additional studies, melatonin 
modulates the release of Ach in the nucleus 
accumbens and can alter functions of reward 
system in the rats. Melatonin receptors have an 
antinociceptive activity in melatonin in formalin-
induced pain response. This study showed 
that the antinociceptive action of melatonin is 
mediated by the release of opioid-like peptides 
in particular of the brain, such as nucleus 
accumbens.8 Pretreatment with melatonin 
significantly attenuated the anxiolytic-like 
effects of rats withdrawn from repeated cocaine 
administration, which could be used as a novel 
treatment for cocaine dependency.12,13 In cocaine 
dependent mice, physical withdrawal syndromes 
are inhibited by melatonin.14 On the other hand, 
morphine withdrawal is characterized by an 
increase in the activity of hypothalamus-pituitary-
adrenocortical (HPA) axis and an increase in 
corticosterone secretion and blood cortisol levels, 
as corticosterone is responsible for stress and 
anxiety of the withdrawal period.15,16 Since mRNA 
expression is required for the synthesis of the CRH 
(corticotrophin releasing hormone) and opioid 
dependency increase mRNA expression, opioid 
dependency has a positive effect on the secretion 
of cortisol.16,17 Also, previous studies have 
indicated that melatonin has potential anxiolytic 
effects.18 Melatonin is effective in reducing the 
postoperative anxiety of morphine consumption.19 
Recent data demonstrated anxiolytic properties of 
melatonin type-2 receptors.18 These results show 
that, melatonin has high potential for usage as 
an anxiolytic agent and could be used as stress 
modulating medication. 
The aim of this study was to evaluate 
the possible role of intraperitoneal (ip) or 
intracerebroventricular (icv) pre-treatment with 
ramelteon, a melatonin receptor agonist, on 
morphine-induced withdrawal symptoms. In 
addition to the observable signs of morphine 
abstinence, for the assessment of ramelteon on 
anxiety and stress of withdrawal syndrome, blood 
cortisols were also measured. 
 Materials and Methods                                                                                         
The Animals
88 adult male rats (200-250 grams) were 
obtained from Pasteur Institute of Iran and 
transferred to the animal lab of the central 
laboratory of Tehran University of Medical 
Sciences. The animals had free access to 
water and food and were kept in a controlled 
environment with a 12-hour light cycle and 
controlled room temperature of 22±3ºC. The rats 
were kept in the animal house for 7 days without 
any experimental challenge, in order to adapt 
them to their new conditions. All experimental 
procedures followed the guidelines on ethical 
standards for experiment on pain in animals and 
carried out according to a protocol approved by 
the local Animal Ethics Committee
The Drug
Morphine, naloxone and ramelteon and other 
chemical were purchased from Sigma (Aldrich 
Inc., St Louis MO, USA).
The Experimental Groups
Rats were randomly divided into 11 groups, 
namely:
● Group I, as “negative control group” 
(independent) received normal saline (1 ml/kg 
bw, ip) for 9 days.
● Group II, as “positive control group for 
systemic administration of ramelteon” (dependent) 
received morphine with an increasing dosage 
(15-55 mg/kg s.c) for the first 5 days and were then 
received saline solution (1 ml/kg, ip) concurrently 
with the highest dose of morphine once a day 
from day 5 to 9.
● Groups III, IV and V received morphine with 
an increasing dosage (15-55 mg/kg s.c ) for the 
first 5 days and then ramelteon was injected with 
doses of 10, 20 and 40 mg/kg bw, ip, respectively 
and concurrently with morphine once in a day 
from days 5 to 9.
● Group VI, as “positive control group for icv 
administration of ramelteon” (dependent) received 
morphine with an increasing dosage (15-55 mg/
kg s.c) for the first 5 days and then were injected 
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saline solution (1 ml/kg, ip) concurrently with the 
highest dose of morphine once in a day from day 
5 to day 9.
● Groups VII, VIII and IX received morphine 
with an increasing dosage (15-55 mg/kg s.c) 
for the first 5 days and then ramelteon was 
concurrently injected with morphine at dosages 
of 25, 50 or 100 μg/5 μl/rat, icv, from day 5 to day 
9, respectively.
● Groups X and XI were treated just by 
ramelteon (40 mg/kg bw, ip) or ramelteon (100 
μg/5 μl/rat, icv) for 9 days.20,21
For the icv administration, a Hamilton syringe 
was used and connected to a length of PE-10 
polyethylene tubing. Seeing the air bubble 
through the tube confirmed the injection efficacy. 
The volume of each infusion was 5 μl/site at a rate 
of 5 μl/ min for each rat.22
Intracerebroventricular (icv) Cannula Implantation
For icv treatment, animal were anesthetized 
with sodium pentobarbital (55 mg/kg bw, ip) and 
a 23 gauge thin-walled stainless steel guide 
cannula was stereotaxically implanted into 
the lateral cerebral ventricle according to the 
technique described in previous research.22 The 
sterotaxic coordinate with respect to the bregma 
were -0.8 mm posterior, -1.3 mm midline to lateral 
and 3.5 mm ventral. The guide cannula was fixed 
by three stainless steel screws and the mentioned 
screws were sealed with acrylic dental cement 
(pars acryl) in the target area. A dummy cannula 
with 30 gauges trimmed to the exact length of 
guide cannula and was inserted into the guide 
cannula. After surgical insertion of guide cannula 
and before the beginning of the experimental 
protocol, rats were allowed to recover for 7 days. 
During the recovery period, rats were brought to 
the experimental room and gently chandelled and 
removed their dummy cannula for 2 minutes. This 
process was done three times a day.22
Histological Confirmation of Cannula Placement
For the verification of guide cannula placement 
into lateral ventricles, two methods were used, 
(i) the presence of cerebrospinal fluid in guide 
cannula was confirmed and (ii) at the completion 
of each experiment, intracerebroventricular 
injection of methylene blue5 ( μl/rat) was followed 
by anesthetization of rats by pentobarbital. Rats 
were then euthanized by decapitation. Brain tissue 
was removed and visualization of methylene blue 
in the lateral ventricles confirmed that the guide 
cannula was correctly inserted. Data for four rats, 
where the guide cannula had not been inserted 
correctly, was omitted from our study analysis. 
Induction of Morphine Dependency
Morphine dependency was induced in 8 
separate groups by subcutaneous injection of 
morphine in a dose-increasing manner (15-55 
mg/kg) for 5 consecutive days.22 
Induction and Evaluation of Morphine Withdrawal 
Syndrome
In order to induce withdrawal symptoms, all 
rats in each group were injected by naloxone 3 mg/
kg and behaviors of each animal were recorded 
by a camera  for a period of 60 minutes. The 
recorded behavior included jumping, head shake, 
wet dog shake, forepaw tremor, writhing, walking 
sniffing, sniffing, penile liking, rearing, chewing, 
body grooming, face wiping, swallowing, and 
teeth chattering. The number of each behavior 
was divided by their weighing factor (table 1) and 
a value was obtained. The summation of these 
values gave the total withdrawal score (TWS). 
These behavioral syndromes were commutated 
according to the previous studies.22
Measuring the Blood Cortisol 
On the 10th day, after all behavioral signs had 
been recorded; whole blood was collected from 
all animals. Serum was separated from whole 
blood and serum cortisol levels were measured 
in μg/dl by the ELISA method. 
Data Analysis
All data obtained by this study were statistically 
analyzed using GraphPad Prism V6 software. 
The data was averaged in every experimental 
group and expressed as means±standard error 
of the means (SEM). In the next step, differences 
between controls and treatment groups were 
Table 1: Weighing factors (WFs) of different withdrawal signs of morphine in the mouse
Behavior WF Behavior WF
Jumping 4 Body grooming 10
Head shake 5 Face wiping 10
Wet dog shake 5 Swallowing 10
Paw tremor 5 Teeth chattering 10
Writhing 5 Dysphoria 10
Walking sniffing 5 Rearing 20
Sniffing 5 Chewing 20
Penile liking 5  -------- --------
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evaluated by one way ANOVA. Differences 
between severities of behaviors in the treatment 
of each group were evaluated by Dunnett post 
hoc test. A value with P<0.05 was taken as 
statistically significant.
 Results                                                                                         
Total Withdrawal Score (TWS) in Controls 
Groups and Groups under Treatment by Systemic 
Administration of Ramelteon 
The result of our study indicates that TWS in 
the negative control group (group I) during the 
experimental period was 16±1.2 while for positive 
control group (group II) it was 52±2 (P<0.001) 
(figure 1). 
Intraperitoneal administration of ramelteon 
in dosage of 10, 20, or 40 mg/kg (groups III, IV 
and V) caused TWS decreases of 48±1.5, 39±1.6 
and 22±1.4, respectively. Decreases in TWS were 
statistically significant for all three groups (II, IV 
and V) with statistical significance of P<0.001, 
P<0.05 and P<0.001, respectively, as compared 
with the positive control group. Additionally, 
group X, which exclusively received 40 mg/kg of 
ramelteon intraperitoneally, showed significant 
decreases in TWS in comparison with the positive 
control group (figure 2).
Total Withdrawal Score (TWS) in Controls 
Groups and Groups under Treatment by Central 
Administration of Ramelteon 
TWS in the negative control group in which 
received normal saline during the experimental 
period was 16±1.2 while for the positive control 
group (group VI) TWS rate was 53±1.5 (P<0.001) 
(figure 2).
Intracerebroventricular injection of ramelteon 
in a dosage of 25, 50, or 100 μg/5 μl/rat (groups 
VII, VIII and IX) decreased the TWS to 45±1.5, 
31±1.1 and 22±1.4, respectively. This attenuation 
in the group under treatment at the dose of 25 μg/5 
μl/rat was statistically significant with P<0.05, and 
in groups under the treatment with doses of 50 or 
100 μg/5 μl/rat were statistically significant with 
P<0.001 in comparison with the positive control 
group (group VI). Also, group XI, which received 
intracerebroventricular ramelteon at a dose of 
100 ug/5ul/rat, showed significant decreases in 
TWS (17.8±0.9) in comparison with group VI, the 
positive control group (P<0.001) (figure 2).
Effect of Systemic Administration of Ramelteon 
on Blood Cortisol Levels
Our study indicates that blood cortisol levels in 
the negative control group (group I) were 7.8±1.2 
μg/dl, while in the positive control group (group II) 
it was 19±1.2 μg/dl (P<0.001) (figure 3).
Intraperitoneal injection of ramelteon with 
Figure 1: This figure shows total withdrawal score 
(TWS) in dependent group under treatment by systemic 
administration of ramelteon (10, 20, 40 mg/kg, bw), negative 
control group and ramelteon treatment group (40 mg/kg, bw) 
compared with positive control group. Data are expressed 
as the mean±SEM; ***P<0.001 and *P<0.05 different from 
positive control group; M: Morphine, Ramel: Ramelteon             
Figure 3: This figure shows blood cortisol level after the 
injection of naloxone in dependent group under treatment by 
systemic administration of ramelteon (10, 20, 40 mg/kg, bw) 
and negative control group and ramelteon treatment group 
(40 mg/kg, bw) compared with positive control group. Data 
are expressed as the mean±SEM; ***P<0.001 different from 
control positive group; M: Morphine, Ramel: Ramelteon             
Figure 2: This figure shows total withdrawal score (TWS) in 
dependent group under treatment by central administration 
of ramelteon (25, 50 or 100 μg/5 μl/rat, icv), negative control 
group and ramelteon treatment group (100 μg/5 μl/rat, icv) 
compared with positive control group. Data are expressed 
as the mean±SEM; ***P<0.001 and *P<0.05 different from 
positive control group; M: Morphine, Ramel: Ramelteon            
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doses of 10, 20, or 40 mg/kg (groups III, IV and 
V) caused attenuation of blood cortisol levels that 
reached 15±1.5, 12±1.1 and 9±1.1, respectively. 
Augmentation of blood cortisol levels were 
statistically significant (P<0.001) only in groups 
treated with doses of 20 or 40 mg/kg ramelteon. 
In the group under treatment with a ramelteon 
dose of 40 mg/kg (group X), blood cortisol levels 
were 8.5±1.3 and it was statistically significant in 
comparison with the positive control group (group 
II) (P<0.001) (figure 3).
Effect of Central Administration of Ramelteon on 
Blood Cortisol Levels
The blood cortisol level in the negative control 
group was 7.8±1.2 and was 15±1.4 for the positive 
control group (P<0.001) (figure 4).
Intracerebroventricular administration of 
ramelteon in doses of 25, 50 or 100 μg/5 μl/rat 
(groups VII, VIII and IX) attenuated the blood 
cortisol level to 13±1.2, 10±0.5 and 9±0.8, 
respectively. This attenuation in groups under 
treatment with doses of 50 or 100 μg/5 μl/rat was 
statistically significant with P<0.001 in comparison 
with the positive control group (group VI). Group 
XI, which received intracerebroventricular 
ramelteon at a dose of 100 ug/5 ul/rat, showed 
a significant decrease in blood cortisol levels 
(8.9±0.1) as compared with the positive control 
group (group VI) (P<0.001) (figure 4). 
 Discussion                                                                                         
Characterized by withdrawal syndrome, 
long-term use of opioid derivatives, such as 
morphine, results in major health problems like 
dependency. As the results of our study indicate, 
the central administration of ramelteon in multiple 
dosages decreased the withdrawal symptoms 
significantly. Our experiments show that only high 
doses of systemic administration of ramelteon can 
attenuate withdrawal symptoms. Generally, our 
finding confirmed the idea that ramelteon central 
injection would attenuates morphine dependency. 
Previous study demonstrated that ramelteon, a 
non-selective melatonin receptor agonist, has 
a neuroprotective effects, and is used for the 
treatment of some neuroprotective effects and for 
the treatment of some neurodegenerative diseases 
such as Parkinson and Alzheimer.8,23-25 Previous 
study demonstrated that melatonin receptors have 
an antinociceptive activity in pain response; these 
results showed that melatonin has antinociceptive 
action by releasing of opioids like peptide in the brain 
region such as nucleus accumbens. Thus, because 
of this antinociceptive effect, this hormone could be 
beneficial in the attenuation of pain due to morphine 
withdrawal syndrome. The results of the present 
study indicate that, the total withdrawal score in 
central administration of ramelteon with multiple 
doses has a significant difference compared to the 
saline treatment group. However, the group that 
received only a high dose of systemic administration 
alone showed this type of attenuation. Thus, our 
study demonstrated that central administration is 
more effective in decreasing the withdrawal signs. 
Our study confirms the results of previous studies; 
in which pretreatment with melatonin significantly 
reduces the anxiolytic effects of rats experiencing 
withdrawal from repeated cocaine administration 
and that it can be used as a novel treatment 
for cocaine dependency.14,19,26,27 The physical 
withdrawal syndromes in morphine and cocaine 
dependent mice are inhibited by melatonin.14,27 
Since ramelteon is metabolized by the cytochrome 
P-450 system, differences are seemed in the 
administration by the central method versus the 
systemic method. Due to the low metabolism of 
ramelteon, when it is administered centrally, the 
central administration can cause a greater reduction 
in morphine dependency as compared to the 
systemic administration. In addition, it has been 
indicated that ramelteon can protect dopaminergic 
cell from cytotoxicity of 6-hydroxy dopamine (6-HO). 
Furthermore, these studies have also demonstrated 
that ramelteon has an antioxidative properties.28,29 
Previous studies have indicated that 
dopaminergic and serotonergic systems of the 
nucleus accumbens have a critical role in opioid 
dependence.30-33 These studies described 
interactions between pineal melatonin and both 
the serotonergic and dopaminergic systems, 
and suggested that melatonin has potential 
modulator effects on both of these systems; cell 
bodies and associated behavioral effects.30,34 
Figure 4: This figure shows blood cortisol level after the 
injection of naloxone in dependent group under treatment 
treated by central administration of ramelteon (25, 50 
or 100 μg/5 μl/rat, icv) and negative control group and 
ramelteon treatment group (100 μg/5 μl/rat, icv) compared 
with positive control group. Data are expressed as the 
mean±SEM; ***P<0.001 different from control positive 
group; M: Morphine, Ramel: Ramelteon.                                   
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In addition, the results of some other studies 
suggest that melatonin modulates the release of 
dopamine in the nucleus accumbens and plays a 
role in the reward system function in rats.35 This 
study demonstrated that ramelteon can protect 
dopaminergic, serotonergic and cholinergic 
neurons, all of which are involved in morphine 
dependency.35 
Furthermore, morphine withdrawal 
syndrome is characterized by an increase in the 
hypothalamus–pituitary–adrenocortical (HPA) 
axis activity. Morphine dependence increased 
HPA axis activity with changes in corticotrophin 
releasing hormone (CRH) mRNA gene expression 
in selective neurons of the paraventricular 
nucleus.36 Our study demonstrates that central 
and systemic administration of ramelteon can 
attenuate blood concentrations of cortisol in 
withdrawal syndrome periods. Ramelteon 
seems to have anxiolytic effects, which could 
be beneficial in morphine withdrawal attenuation 
signs. Melatonin reduced postoperative anxiety 
and morphine consumption. Thus, melatonin 
receptor agonist, such as ramelteon, can reduce 
withdrawal syndrome anxiety and may be 
beneficial for morphine abandonment treatment. 
Other studies demonstrated anxiolytic properties 
of melatonin type-2 receptors.37 Our study 
showed melatonin has high potential for use as an 
anxiolytic agent for the management and stress-
modulation of withdrawal syndrome. 
 Conclusion                                                                                         
The results of this study show that systemic 
administration of ramelteon at a dose of 20 and 40 mg/
kg significantly attenuates morphine dependence. 
Our study also shows that central administration of 
ramelteon at 25, 50 and 100 μg/5 ul can mitigate 
the total morphine withdrawal syndrome. Lastly, 
systemic administration of ramelteon at 20 and 
40 mg/kg and central administration of ramelteon 
at 50 and 100 μg significantly attenuates blood 
cortisol levels during withdrawal episodes. All of 
these pharmacological actions may be relevant 
to the potential therapeutic effect of ramelteon on 
morphine physical dependence. However, further 
molecular investigations are required to clarify our 
results for the possibility of ramelteon in attenuating 
morphine physical dependency.
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